173 related articles for article (PubMed ID: 34228553)
41. APPLICATION OF OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY TO ASSESS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY IN MYOPIC CHOROIDAL NEOVASCULARIZATION.
Cheng Y; Li Y; Huang X; Qu Y
Retina; 2019 Apr; 39(4):712-718. PubMed ID: 29256987
[TBL] [Abstract][Full Text] [Related]
42. FACTORS INFLUENCING NEED FOR RETREATMENT AND LONG-TERM VISUAL OUTCOME AFTER INTRAVITREAL BEVACIZUMAB FOR MYOPIC CHOROIDAL NEOVASCULARIZATION.
Ng DS; Kwok AK; Tong JM; Chan CW; Li WW
Retina; 2015 Dec; 35(12):2457-68. PubMed ID: 26035400
[TBL] [Abstract][Full Text] [Related]
43. The Evaluation of a Two-Year Outcome of Intravitreal Conbercept versus Ranibizumab for Pathological Myopic Choroidal Neovascularization.
Chen C; Yan M; Huang Z; Song YP
Curr Eye Res; 2020 Nov; 45(11):1415-1421. PubMed ID: 32191134
[No Abstract] [Full Text] [Related]
44. Effect of intravitreal ranibizumab injections on aqueous humour concentrations of vascular endothelial growth factor and pigment epithelium-derived factor in patients with myopic choroidal neovascularisation.
Costagliola C; Semeraro F; dell'Omo R; Romano MR; Russo A; Aceto F; Mastropasqua R; Porcellini A
Br J Ophthalmol; 2015 Jul; 99(7):1004-8. PubMed ID: 25770144
[TBL] [Abstract][Full Text] [Related]
45. HOW VITREOMACULAR INTERFACE MODIFIES THE EFFICACY OF ANTI-VEGF THERAPY FOR MYOPIC CHOROIDAL NEOVASCULARIZATION.
Iacono P; Battaglia Parodi M; Iuliano L; Bandello F
Retina; 2018 Jan; 38(1):84-90. PubMed ID: 28098725
[TBL] [Abstract][Full Text] [Related]
46. Long-term functional and morphologic retinal changes after ranibizumab and photodynamic therapy in myopic choroidal neovascularization.
Parravano M; Ricci F; Oddone F; Missiroli F; De Felici C; Varano M
Retina; 2014 Oct; 34(10):2053-62. PubMed ID: 24946101
[TBL] [Abstract][Full Text] [Related]
47. Myopic choroidal neovascularisation: current concepts and update on clinical management.
Wong TY; Ohno-Matsui K; Leveziel N; Holz FG; Lai TY; Yu HG; Lanzetta P; Chen Y; Tufail A
Br J Ophthalmol; 2015 Mar; 99(3):289-96. PubMed ID: 24990871
[TBL] [Abstract][Full Text] [Related]
48. Long-term outcomes of the intravitreal injection of ranibizumab for the treatment of choroidal neovascularization secondary to pathologic myopia.
Wasiluk E; Wojnar M; Obuchowska I; Mariak Z
Int Ophthalmol; 2020 Apr; 40(4):833-839. PubMed ID: 31788714
[TBL] [Abstract][Full Text] [Related]
49. [Intravitreal anti-VEGF treatment of choroidal neovascularization (CNV) in pathological myopia (PM): a review].
Hefner L; Gerding H
Klin Monbl Augenheilkd; 2014 Apr; 231(4):414-7. PubMed ID: 24771180
[TBL] [Abstract][Full Text] [Related]
50. Result of intravitreal aflibercept injection for myopic choroidal neovascularization.
Chen SL; Tang PL; Wu TT
BMC Ophthalmol; 2021 Sep; 21(1):342. PubMed ID: 34551746
[TBL] [Abstract][Full Text] [Related]
51. Summary of prognostic factors for choroidal neovascularization due to pathological myopia treated by intravitreal bevacizumab injection.
Wang J; Kang Z
Graefes Arch Clin Exp Ophthalmol; 2012 Dec; 250(12):1717-23. PubMed ID: 23007232
[TBL] [Abstract][Full Text] [Related]
52. Association between choroidal morphology and anti-vascular endothelial growth factor treatment outcome in myopic choroidal neovascularization.
Ahn SJ; Woo SJ; Kim KE; Park KH
Invest Ophthalmol Vis Sci; 2013 Mar; 54(3):2115-22. PubMed ID: 23462751
[TBL] [Abstract][Full Text] [Related]
53. Prognostic factors of eyes with naïve subfoveal myopic choroidal neovascularization after intravitreal bevacizumab.
Yang HS; Kim JG; Kim JT; Joe SG
Am J Ophthalmol; 2013 Dec; 156(6):1201-1210.e2. PubMed ID: 24075429
[TBL] [Abstract][Full Text] [Related]
54. Pilot study of ziv-aflibercept in myopic choroidal neovascularisation patients.
Nawar AE; Shafik HM
BMC Ophthalmol; 2020 Oct; 20(1):414. PubMed ID: 33076864
[TBL] [Abstract][Full Text] [Related]
55. Comparison of 1-year therapeutic effect of ranibizumab and bevacizumab for myopic choroidal neovascularization: a retrospective, multicenter, comparative study.
Cha DM; Kim TW; Heo JW; Woo SJ; Park KH; Yu HG; Chung H
BMC Ophthalmol; 2014 May; 14():69. PubMed ID: 24884970
[TBL] [Abstract][Full Text] [Related]
56. Risk factors for subretinal fibrosis after anti-VEGF treatment of myopic choroidal neovascularisation.
Xiao H; Zhao X; Li S; Sun L; Xin W; Wang Z; Zhang A; Zhang J; Ding X
Br J Ophthalmol; 2021 Jan; 105(1):103-108. PubMed ID: 32161005
[TBL] [Abstract][Full Text] [Related]
57. Safety and complications of intravitreal injections performed in an Asian population in Singapore.
Xu Y; Tan CS
Int Ophthalmol; 2017 Apr; 37(2):325-332. PubMed ID: 27236451
[TBL] [Abstract][Full Text] [Related]
58. Choroidal neovascularization in pathologic myopia: intravitreal ranibizumab versus bevacizumab--a randomized controlled trial.
Gharbiya M; Giustolisi R; Allievi F; Fantozzi N; Mazzeo L; Scavella V; Gabrieli CB
Am J Ophthalmol; 2010 Mar; 149(3):458-64.e1. PubMed ID: 20172072
[TBL] [Abstract][Full Text] [Related]
59. Three-year real-world outcomes of intravitreal anti-VEGF therapies in patients affected by myopic choroidal neovascularization.
Corazza P; Kabbani J; Soomro T; Alam MMR; D'Alterio FM; Younis S
Eur J Ophthalmol; 2021 Sep; 31(5):2481-2487. PubMed ID: 33135487
[TBL] [Abstract][Full Text] [Related]
60. A new treatment algorithm for the management of myopic choroidal neovascularization using intravitreal ranibizumab.
Iacono P; Parodi MB; Papayannis A; La Spina C; Varano M; Bandello F
Acta Ophthalmol; 2015 Sep; 93(6):e519-20. PubMed ID: 25828793
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
